With 4.52 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.78 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $17.2799 whereas the lowest price it dropped to was $16.42. The 52-week range on TGTX shows that it touched its highest point at $35.22 and its lowest point at $6.46 during that stretch. It currently has a 1-year price target of $31.50. Beta for the stock currently stands at 2.30.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TGTX was up-trending over the past week, with a rise of 25.77%, but this was up by 14.76% over a month. Three-month performance surged to 11.92% while six-month performance rose 55.33%. The stock lost -49.90% in the past year, while it has gained 0.59% so far this year. A look at the trailing 12-month EPS for TGTX yields 0.22 with Next year EPS estimates of 0.59. For the next quarter, that number is -0.04. This implies an EPS growth rate of -138.27% for this year and 1820.18% for next year.
Float and Shares Shorts:
At present, 151.42 million TGTX shares are outstanding with a float of 139.77 million shares on hand for trading. On 2024-04-15, short shares totaled 35.71 million, which was 2313.0 higher than short shares on 1710460800. In addition to Mr. Michael S. Weiss Esq. as the firm’s Chairman, CEO & President, Mr. Sean A. Power CPA serves as its CFO, Corporate Secretary & Treasurer.
Institutional Ownership:
Through their ownership of 0.59041 of TGTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, TGTX reported revenue of $43971000.0 and operating income of -$12485000.0. The EBITDA in the recently reported quarter was -$11504000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TGTX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
